Brukinsa

USDailyMed:Zanubrutinib AU:D L01EL03(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-onlyRx-only 1691249-45-2 135565884 DB15035 64835237 AG9MHG098Z D11422 ChEMBL3936761 BA0 (PDBe,RCSB PDB) Interactive image NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1 InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14‍‍‍‍‍‍​​​‍​​​​​​-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1Key:RNOAOAWBMHREKO-QFIPXVFZSA-N Zanubrutinib, sold under the brand nameBrukinsa, is ananticancer medicationused for the treatment ofmantle cell lymphoma(MCL),Waldenström's macroglobulinemia(WM),marginal zone lymphoma(MZL), andchronic lymphocytic leukemia(CLL).Zanubrutinib is classified as aBruton's tyrosine kinase(BTK) inhibitor.It is givenby mouth. It was approved for medical use in the United States in November 2019.Zanubrutinib is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.